Analysis of immunocytochemical and molecular BRAF expression in thyroid carcinomas: A cytohistologic institutional experience

Esther Rossi, Maurizio Martini, Celestino Pio Lombardi, Alfredo Pontecorvi, Luigi Maria Larocca, Sara Capodimonti, Tonia Cenci, Patrizia Straccia, Basilio Angrisani, Paola Lanza, Guido Fadda

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

It has been generally demonstrated that the valine-to-glutamic acid substitution at position 600 (V600E) in the v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) gene is an effective diagnostic/prognostic marker mainly for papillary thyroid carcinoma (PTC). The detection of this mutation typically has been achieved using DNA-based techniques. The recently introduced monoclonal V600E antibody (clone VE1) is likely to be an alternative strategy for detecting this mutation in thyroid lesions. The authors investigated molecular and immunocytohistochemical BRAF analyses in a prospective series of samples from patients with PTC.
Original languageEnglish
Pages (from-to)N/A-N/A
JournalCancer cytopathology
DOIs
Publication statusPublished - 2014

Keywords

  • BRAF mutation
  • VE1 immunomarker
  • immunochemistry
  • liquid-based cytology
  • thyroid papillary carcinoma

Fingerprint

Dive into the research topics of 'Analysis of immunocytochemical and molecular BRAF expression in thyroid carcinomas: A cytohistologic institutional experience'. Together they form a unique fingerprint.

Cite this